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ABSTRACT
Chronic myeloid leukemia (CML) is characterized by a constitutive activation 
of Bcr-Abl tyrosine kinase. Bcr-Abl/T315I is the predominant mutation that causes 
resistance to Imatinib. In the present study, we synthesized a novel Bcr-Abl inhibitor, 
HS-543, and investigated its effect on cell survival or apoptosis in CML cells bearing 
Bcr-Abl/T315I (BaF3/T315I) or wild-type Bcr-Abl (BaF3/WT). HS-543 showed 
anti-proliferative effects in the BaF3/WT cells as well as the BaF3/T315I cells with 
resistance to Imatinib and strongly inhibited the Bcr-Abl signaling pathway in a 
dose‑dependent manner. Furthermore, it significantly increased the sub G1 phase 
associated with early apoptosis, with increased levels of cleaved PARP and cleaved 
caspase-3, as well as the TUNEL-positive apoptotic cells. In addition, we found that 
HS-543 induced apoptosis with the loss of mitochondrial membrane potential by 
decreasing the expression of Mcl-1 and survivin, together with increasing that of Bax. 
In BaF3/T315I xenograft models, HS‑543 significantly delayed tumor growth, unlike 
Imatinib. Our results demonstrate that HS-543 exhibits the induction of apoptosis 
and anti-proliferative effect by blocking the Bcr-Abl signaling pathway in the T315I-
mutated Bcr-Abl cells with resistance to Imatinib. We suggest that HS-543 may be 
a novel promising agent to target Bcr-Abl and overcome Imatinib resistance in CML 
patients.
INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal 
myeloproliferative disorder that is characterized by high 
levels of immature white blood cells, which is one of the 
most understood neoplasms. Annually, newly diagnosed 
cases of CML in the United States is estimated to be about 
4,800 to 5,200. The estimated prevalence of CML cases 
in the United States was approximately 25,000~30,000. 
CML is defined by the formation and presence of the 
Philadelphia (Ph) chromosome, which results from 
the reciprocal chromosomal translocation t(9;22) and 
is represented as Bcr–Abl fusion gene. This Bcr–Abl 
fusion protein is found in ~95% of patients with CML 
and 20~30% of adult patients with acute lymphoblastic 
leukemia (ALL) [1], a lesser extent Bcr-Abl+ ALL [2]. The 
Bcr–Abl aberrant tyrosine kinase is mainly responsible 
for malignant transformation by activating multiple 
signal transduction pathways including Stats, MAPK/
Erk, and PI3K/Akt, which ultimately lead to increased 
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survival, proliferation, and escape from apoptosis [3, 
4]. For this reason, Bcr–Abl tyrosine kinase has been 
considered as an important target for CML therapeutics. 
Meanwhile, Imatinib is considered as the first selective 
Bcr–Abl tyrosine kinase inhibitor (TKI) for cancer 
therapy, which interrupts Bcr–Abl oncogenic signaling. 
Therefore, Imatinib has become the new “gold standard” 
for the treatment of patients with CML. Especially, 80% 
of newly diagnosed patients with chronic-phase CML has 
shown a complete cytogenetic response to treatment with 
Imatinib over a median follow-up of 54 months. Although 
the initial response rates are high, Imatinib fails in up to 
40% of patients because of disease resistance or Bcr-Abl 
kinase domain mutations, and unacceptable side effects. 
To circumvent the resistance, more potent TKIs such as 
Nilotinib and Dasatinib as the second generation TKIs, 
have been approved. However, these compounds do not 
show therapeutic activities against all Imatinib-resistant 
mutants of Bcr-Abl, and finally a long-term tolerablility 
problem has emerged.
Drug resistance during the Imatinib treatment is 
mostly related to point mutations occurring within the 
kinase domain of Bcr-Abl. To date, over 90 different point 
mutations in the Bcr-Abl kinase domain have been isolated 
from relapsed CML patients, who are resistant to Imatinib. 
Among those, the T315I is the most stubborn point 
mutation having an impact on the binding of Imatinib with 
Bcr-Abl kinase domain. Also, the T315I is responsible 
for approximately 15% of the cases of relapse in CML 
and Bcr-Abl+ ALL patients on Imatinib therapy [5], and 
there is high occurrence of E255K and M351T mutations 
[6, 7]. Most mutations, except T315I, may be eradicated 
with the appropriate choice and combinations of second 
generation tyrosine kinase inhibitors. However, there is 
still no effective TKI available for CML with the T315I 
mutation. Considering these facts, the T315I mutation 
remains a crucial clinical challenge, and it is imperative 
to develop novel strategies to overcome this resistance.
To resolve these problems, we synthesized 
and screened a chemical library of novel series of 
benzothiazole-based inhibitors that are effective against 
wild-type and T315I mutant Bcr-Abl kinases [8]. Of the 
benzothiazole-based inhibitors, 1-(6-(2- methoxyphenyl)
benzo[d]thiazol-2-yl)-3-(2-(4-methylpiperazin-1-yl)ethyl), 
HS-543 was identified as the potent Bcr-Abl kinases 
inhibitor. Here, we investigated whether or not HS-543 
possesses anti-cancer activity in BaF3/T315I or BaF3/WT 
and the molecular mechanisms involved in this process. 
In this study, our results showed that HS-543 suppressed 
the Bcr-Abl pathway and induced apoptosis in not only 
BaF3/WT cells but also T315I-mutated Bcr-Abl cells with 
resistance to Imatinib.
RESULTS
Synthesis of HS-543 and its binding mode to Bcr-
Abl
We identified a novel Bcr-Abl inhibitor, 
1-(6-(2-methoxyphenyl)benzo[d]thiazol-2-yl)-3-(2-(4-
methylpiperazin-1-yl)ethyl) urea or HS-543. As shown 
in Table 1, HS-543 was further subjected to kinase 
selectivity profiling against a panel of cancer-related 
kinases at 1 μM concentrations in a high-throughput 
binding assay (KINOMEscan®, Ambit Biosciences, San 
Diego, CA). Percent of control (POC) determinations were 
also performed. HS-543 displayed only a high degree of 
selectivity to Abl but not to other kinases such as Aurora 
and c-Kit, which are known to have high structural 
similarities to Abl. The only kinases against which HS-
543 demonstrated target activity were Abl (POC 1.6) and 
Abl/T315I (POC 3.1). We prepared the receptor model in 
DFG-in conformation from the X-ray crystal structure of 
T315I mutant in a complex with PPY-A (PDB code: 2Z60) 
[9]. Fig. 1 shows the possible binding mode of HS-543 
in the ATP binding site of T315I mutant Abl, which was 
obtained through a docking simulation using the Autodock 
Figure 1: Structure and predicted binding mode 
of HS-543 with Abl/T315I. (A) Structure of HS-543, 
1-(6-(2-methoxyphenyl)benzo[d]thiazol-2-yl)-3-(2-(4-methyl 
piperazin-1-yl)ethyl)urea. (B) The putative binding mode of HS-
543 in the Bcr-Abl model.
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program [10]. The docking simulation indicated that C6 
methoxyphenyl moiety was surrounded by a hydrophobic 
pocket, and methyl piperazine moiety in C2 urea was 
expected to the solvent front. In the hinge region, the 
nitrogen of benzothiazole scaffold and the C2 urea group 
appeared to form a tight hydrogen bond with the backbone 
residue of Met318 in the hinge region. Especially, both of 
the two NHs in the distorted C2 urea group appeared to 
act as hydrogen bond donors and form hydrogen bonds 
with aminocarbonyl oxygen of the Met318 backbone. 
C6 aryl moiety was directed toward the region nearby 
the gatekeeper and catalytic lysine. The C6 phenyl ring 
seemed to form favorable van der Waals interactions with 
the larger mutated gatekeeper, Ile318, without causing 
steric hindrance. In addition, the oxygen of the 2’-methoxy 
group in the C6 phenyl ring could contribute to an 
additional hydrogen bond with the Asp381 backbone. 
HS-543 inhibits the proliferation of leukemia cells
MTS assays were performed to evaluate the effect of 
HS-543 on the growth of BaF3/WT and BaF3/T315I cells. 
The cells were treated with various concentrations of HS-
543 and Imatinib for 48 h. As shown in Fig. 2A, both HS-
543 and Imatinib treatments reduced the cell viability of 
the BaF3/WT cells; IC50 values were 0.33 μM for Imatinib 
and 0.116 μM for HS-543. As shown in Fig. 2B, HS-543 
significantly reduced the cell viability of BaF3/T315I 
cells (IC50 = 0.33 µM), while Imatinib showed little effect 
(IC50 = 10 μM). These data suggest that HS-543 exhibits 
the potent inhibitory activity in T315I mutated Bcr-Abl 
Table 1: High-throughput binding assay against a panel of kinases. A panel of 96 kinases was tested at 1 μM 
concentrations in a high-throughput binding assay. Only representative kinases are shown here. Lower percent of 
control (POC) values represent stronger hits. Values shown are the mean of duplicate measurements.
KINOME scan Gene Symbol Entrez Gene Symbol  POC Compound Concentration (nM)
ABL1(T315I)
-phosphorylated ABL1 3.1 1000
ABL1-phosphorylated ABL1 1.6 1000
AKT1 AKT1 94 1000
AURKA AURKA 100 1000
BRAF BRAF 92 1000
CDK11 CDK19 91 1000
EGFR EGFR 87 1000
ERK1 MAPK3 100 1000
FAK PTK2 100 1000
FGFR1 FGFR1 80 1000
GSK3B GSK3B 100 1000
IKK-beta IKBKB 100 1000
JAK1(JH1domain-catalytic) JAK1 100 1000
KIT KIT 58 1000
KIT(D816V) KIT 86 1000
MEK1 MAP2K1 100 1000
MET MET 74 1000
P38-alpha MAPK14 100 1000
PAK1 PAK1 88 1000
PIK3CA PIK3CA 100 1000
PIM1 PIM1 98 1000
PLK1 PLK1 88 1000
ROCK1 ROCK1 100 1000
TRKA NTRK1 95 1000
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cells with the resistance to Imatinib, as well as Bcr-Abl 
expressing leukemic cells.
HS-543 inhibits Bcr-Abl signaling pathway in 
BaF3/T315I cells
To test if the antiproliferative effects of HS-543 
were dependent on the inhibition of Bcr-Abl activity, 
phosphorylation of Bcr-Abl and its respective downstream 
signals, Crkl and Stat5, were measured by western 
blotting. As shown in Fig. 3A and 3B, HS-543 strongly 
inhibited the phosphorylation of Bcr-Abl (Tyr177) in BaF3/
T315I cells. Likewise, the phosphorylation levels of Crkl 
(Tyr207) and Stat5 (Tyr694) were effectively suppressed in 
a dose- and time-dependent manner. In contrast, Imatinib 
did not alter the phosphorylation levels of Bcr-Abl, 
Crkl and Stat5 in BaF3/T315I cells. These results were 
confirmed by a confocal fluorescent microscopy (Fig. 3C). 
HS-543 induces apoptotic cell death in BaF3/
T315I cells
In order to determine whether the anti-cancer effect 
of HS-543 in BaF3/T315I cells was associated with 
the induction of apoptosis, we performed several cell-
based apoptosis assays. We first assessed the cell cycle 
distribution by a flow cytometric analysis. The cells were 
collected, stained with PI, and analyzed by flow cytometry 
after they were incubated with HS-543 for various doses 
and times. As shown in the Fig. 4A, HS-543 increased 
the number of cells in the sub G1 phase, associated with 
early apoptosis without changes of the cell cycle arrest. To 
characterize nuclear morphology, the nuclei were stained 
with Hoechst, and a TUNEL assay was performed. As a 
result, the cells treated with HS-543 were presented with 
more prominent morphological features of apoptotic cells, 
such as bright nuclear condensation by Hoechst staining 
(Fig. 4B). HS-543-induced apoptosis was confirmed by 
detecting DNA fragmentation using TUNEL staining. 
Cells were treated with HS-543 for 24 h (Fig. 4C, **p 
<0.001). Furthermore, HS-543 significantly increased 
the expression of cleaved PARP and cleaved caspase-3, 
apoptosis-related molecules in BaF3/T315I cells (Fig. 4D), 
compared with Imatinib. An increase of cleaved caspase-3 
was also confirmed by immunofluorescence after treating 
with 1 μM HS-543 in BaF3/T315I cells for 24 h (Fig. 4E).
Figure 2: Cytotoxic effect of HS-543 in leukemia 
cells. Cytotoxic effects of leukemia cells treated with HS-543 
and Imatinib were measured using the MTS assay. Cells were 
seeded in 96-well culture plates, and were treated with various 
concentrations of HS-543 and Imatinib. Cells were subjected 
to an MTS assay following incubation for 48 h. Data are 
represented as mean ± S.D. from triplicate wells.
Figure 3: Effect of HS-543 on the Bcr-Abl signaling 
pathway in BaF3/T315I cells. (A) Cell were treated with 
HS-543 (0.01–10 μM) or Imatinib (1 μM) for 24 h. Western blot 
experiments for Bcr-Abl, Crkl, and Stat5, and the respective 
phosphorylated proteins were performed with cell lysates. (B) 
Cells were treated with HS-543 for time-dependent manner. 
(C) After BaF3/T315I cells were treated with 10 μM HS-543 
for 3 h, p-Bcr-Abl and p-Stat5 levels were detected by confocal 
fluorescent microscopy (200× magnification).
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HS-543 induces mitochondria-dependent 
apoptosis in BaF3/T315I cells
Loss of mitochondrial membrane potential (MMP) 
induces mitochondrial permeability transition and 
cytosolic translocation of apoptotic proteins [11]. Thus, 
we measured MMP and apoptosis in HS-543-treated 
BaF3/T315I cells using TMRE. As shown in Fig. 5A, 
HS-543 significantly reduced the fluorescence intensity 
reflecting MMP (*p < 0.01). Since MMP can trigger the 
release of mitochondrial cytochrome c into the cytosol and 
induces mitochondria-mediated protein families such as 
Mcl-1, survivin and Bax, we investigated their expression 
by HS-543 in BaF3/T315I cells [9]. As shown in Fig. 
5B, we observed that the treatment of HS-543 increased 
cytochrome c release by immunostaining and western 
blotting. In addition, HS-543 increased the expression of 
Bax and decreased the expression of the anti-apoptotic 
proteins survivin and Mcl-1 (Fig. 5C). These results 
showed that HS-543 induced apoptosis through change of 
mitochondria-related proteins in BaF3/T315I cells.
Figure 4: Effect of HS-543 on apoptosis of BaF3/T315I cells. (A) Cells were incubated with HS-543 for various dose and times. 
Control and treated cells were collected, stained with PI, and analyzed by flow cytometry. (B) Cell were treated with HS-543 (1 μM) for 
24 h. Then, cells were fixed in ice-cold 4% PFA, washed with PBS, and then stained with 1 μg/ml Hoechst 33342 for 20 min at room 
temperature. The stained cells were examined under immunofluorescence for evidence of nuclear fragmentation (400× magnification). (C) 
Cells were treated with HS-543 for 24 h and were performed with TUNEL assay. Data are represented as mean ± S.D. from triplicate wells. 
**p < 0.001 as compared to control. (D) For detection of expression of cleaved PARP and cleaved caspase-3, the cells were treated with 
HS-543 and Imatinib for 36 h. (E) (E) Immunofluorescence of cleaved caspase-3 after treatment of HS-543 (1 μM) in BaF3/T315I cells for 
24 h (400× magnification).
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HS-543 inhibits tumor growth in mouse xenograft 
models
We extended our study to an in vivo mouse 
xenograft model. After inoculation with BaF3/T315I cells, 
mice were intraperitoneally injected with HS-543 at doses 
of 30 and 50 mg/kg, and Imatinib at a dose of 50 mg/
kg 5 times a week for 14 days. While Imatinib treatment 
didn’t show significant anticancer effect in this BaF3/
T315I cell xenograft model, HS-543 potently inhibited 
the progression of tumor growth and more visible and 
significant on day 14 as compared with the control 
group (*p < 0.01, Fig. 6A). Isolated tumor weight was 
also remarkably lower in the HS-543 treated group than 
in the control group (Fig. 6B, *p < 0.01). No significant 
changes in body weight or adverse effect were observed 
in all groups. To further confirm whether HS-543 inhibits 
tumor growth through the induction of apoptosis and 
inhibition of proliferation, we identified the expression 
of cleaved caspase-3 and PCNA in the isolated tumor 
tissues. As expected, the treatment with HS-543 increased 
the expression of cleaved caspase-3 and decreased for 
PCNA in the HS-543 treated group as compared to the 
control and Imatinib groups (Fig. 7A). Furthermore, the 
treatment with HS-543 decreased the phosphorylation of 
Figure 5: Effect of HS-543 on mitochondria-related apoptosis of BaF3/T315I cells. (A) BaF3/T315I cells were treated with 
HS-543 at 1 μM for 12 h and were stained with TMRE for 30 min at 37°C and analyzed with a confocal fluorescent microscopy (400× 
magnification). *p < 0.01 as compared to control. (B) BaF3/T315I cells were treated with HS-543 at 1 μM for 10 h and were stained with 
mitotracker and cytochrome c. Localization of cytochrome c in the cytosol by HS-543 was analyzed with a confocal fluorescent microscopy 
(1200× magnification). For western blotting, BaF3/T315I cells were treated with 0.1 and 1 μM HS-543 together with 1 μM Imatinib for 12 
h. (C) The expression of Mcl-1, survivin and Bax were assayed by western blot in BaF3/T315I cells. Cells were treated with HS-543 and 
Imatinib for 12 h.
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p-Bcr-Abl and p-Stat5; thus, regulating many different 
events involved in cell survival and proliferation (Fig. 
7B). Taken together, these results demonstrate that HS-543 
has a potent antitumor efficacy in mouse xenograft model 
bearing BaF3/T315I cells.
DISCUSSION
In 95% of CML cases, the product of a reciprocal 
translocation between chromosomes 9 and 22, the 
Philadelphia chromosome, is detected, which is 
characterized by the presence of Bcr–Abl fusion gene, 
representing a subtype of leukemia with poor prognosis, 
rapidly acquiring resistance to the Imatinib treatment 
during therapy [12, 13]. Imatinib is the molecular targeted 
agent that selectively inhibits the Bcr–Abl tyrosine kinase 
activity. To date, Imatinib has been recognized as a 
revolutionary treatment of CML, due particularly to 
the durable remission most chronic-phase patients 
experience. Also, Imatinib inhibits Bcr–Abl kinase with 
50% inhibitory concentration values of 0.1–0.5 µM in 
cell-based assays [14, 15]. Targeted therapy to inhibit 
the oncogene Bcr-Abl seems to be somewhat successful. 
However, Imatinib resistance often occurs in patients 
especially in CML accelerated phase and blast crisis, 
and almost unrelievedly occurs in patients with the Bcr-
Abl expression, showing shortcomings of the therapy. 
According to Imatinib resistance, amplification and 
mutation of Bcr-Abl is believed to be the predominant. 
To overcome this acquired resistance to Imatinib, a lot 
of researchers have developed a new, second-generation 
ATP-competitive Abl kinase inhibitors, such as AMN107, 
Dasatinib, INNO-406 and PD166326, which have stronger 
affinities for the ATP-binding site of Bcr-Abl kinase 
than Imatinib, and has shown partial effect for Imatinib-
resistant patients [16-20]. Although these novel inhibitors 
can effectively inhibit the phosphorylation of the mutated 
Bcr-Abl (E255K and M351T), they showed little effect 
on Bcr-Abl/T315I [21]. Therefore, innovative treatment 
is necessary to over-ride TKI-resistant mutations, or 
to promote elimination of Bcr-Abl harboring cells in 
patients. The principal objective of this study is to identify 
Figure 6: In vivo anticancer effect of HS-543 in mouse 
xenograft model. (A) Tumor growth of BaF3/T315I xenograft 
in BALB/c nude mice. All mice were subjected to implantation 
in the flank by a subcutaneous injection of BaF3/T315I (1×105 
cells/200 μL PBS). HS-543 (30 and 50 mg/kg) and Imatinib 50 
mg/kg was intraperitoneally injected 5 times a week for 14 days. 
Tumor size was measured every 2 days. Data were represented 
as mean ± S. D. (n = 5). (B) After mouse sacrifice, representative 
photographs and mean weights of the isolated tumors. *p < 0.01 
as compared to control.
Figure 7: Effect of HS-543 on proliferation and 
apoptosis in isolated tumor from mouse xenograft 
model. (A) Tumors were excised and processed for 
immnunohistochemistry to detect cleaved caspase-3 and PCNA 
including H&E staining. (B) Tumors were stained with p-Bcr-
Abl and p-Stat5 and were detected by confocal fluorescent 
microscopy (400× magnification).
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the effective targeted chemotherapy against CML cells 
carrying T315I-mutant Bcr-Abl that confers resistance to 
Imatinib. In this study, we demonstrated that HS-543, a 
novel Bcr-Abl TKI, had high affinity for the ATP-binding 
site, resulting in high specificity to BaF3/T315I (Table 1). 
In light of these results, we investigated whether HS-543 
had potent activity on Bcr-Abl target inhibition in BaF3/
WT and BaF3/T315I CML cell lines. HS-543 potently 
inhibited the proliferation in both BaF3/WT (IC50 = 0.116 
µM) and BaF3/T315I (IC50 = 0.33 µM) cells. However, 
Imatinib did not inhibit the proliferation in BaF3/T315I 
cells, since IC50 values were more than 10 μM.
Bcr-Abl activates multiple downstream signaling 
pathways, including Stat5 pathway, which contribute to 
leukemic cell proliferation and survival [22, 23]. Also, 
the Stat5 activation is mediated by the adaptor protein 
Crkl [24, 25]. In addition, Stat5 activity appears to play 
a major role in the antiapoptotic and proliferative abilities 
of Bcr-Abl transformed cells [22, 23]. Previous studies 
have established phosphorylation of Stat5 as an indicator 
of Bcr-Abl activity [26]. Therefore, we identified whether 
HS-543 could inhibit Bcr-Abl signaling pathway. As 
expected, HS-543 distinctly inhibited the phosphorylation 
of Bcr-Abl, which indicates decreased Abl kinase activity, 
as well as a pronounced inhibition of Bcr-Abl downstream 
target Stat5 phosphorylation in BaF3/T315I cells. 
Also, phosphorylation of another well-known Bcr-Abl 
downstream target Crkl was obviously reduced after the 
treatment with HS-543. Interestingly, Imatinib inhibited 
the phosphorylation of Bcr-Abl pathways, such as Bcr-
Abl, Stat5, and Crkl in BaF3/WT cells, but not in BaF3/
T315I cells. These results revealed that the decrease of 
phosphorylation of Crkl and Stat5 by HS-543 in the cells 
with the highly resistant mutation T315I was significant, 
which indicate an effective inhibition of Bcr-Abl carrying 
this highly resistant mutation.
Also, HS-543 induces mitochondrial apoptosis in 
BaF3/T3151 cells. In fact, apoptosis has been noticed 
to be associated with a loss of mitochondrial membrane 
potential, which may correspond to the opening of an outer 
membrane pore, leading to the release of cytochrome c 
into the cytoplasm [27]. Also, the release of cytochrome c 
induces the expression of various pro-apoptotic proteins in 
cytoplasm [28]. Especially, Bax initiates a mitochondrial 
permeability shift and induces apoptosis by moving from 
the cytosol to the mitochondrial membrane [29]. And, 
Mcl-1 and survivin as anti-apoptotic proteins have been 
reported to bind to caspases to inhibit apoptosis signaling 
[30]. More importantly, Bcr-Abl inhibits apoptosis through 
regulating Bcl-2 family members [31], increasing the 
expression of antiapoptotic Bcl-2 family members, such 
as Bax and Bcl-2 through activation of the transcription 
factor Stat5 [32-34]. Additionally, Bcr-Abl has been 
shown to prevent mitochondrial cytochrome c release 
through a posttranslational mechanism [35]. Accordingly, 
we assumed that HS-543 would affect the mitochodrial 
membrane potential and induce apoptosis since HS-543 
showed a high specific inhibition against Bcr-Abl. Indeed, 
we observed that HS-543 increased cytochrome c release 
and decreased the expression of Mcl-1 and survivin, 
whereas increased the expression of Bax. These changes 
led to an increase the expression of cleaved caspase-3 and 
cleavage of PARP. These events were supported by in vivo 
results, showing that HS-543 inhibited the tumor growth 
and induced apoptosis by increasing the expression of 
cleaved caspase-3 in tumor tissues of BaF3/T315I cells 
xenograft mice. However, Imatinib did not change the 
expression of apoptosis-related molecules in vitro and in 
vivo. Overall, HS-543 showed to induce apoptosis via an 
intrinsic mitochondria-dependent pathway in BaF3/T315I 
cells, suggesting that the apoptosis effect by HS-543 may 
be achieved by inhibition of Bcr-Abl signaling pathways. 
In conclusion, our results showed that the novel 
selective Bcr-Abl TKI, HS-543, had potent anticancer 
activity against the cells bearing wild type and T315I 
mutant type Bcr-Abl. Given the mechanism of action and 
the promising activity of HS-543 against Imatinib-resistant 
CML cells, our results provide an important vision to 
be considered for future clinical investigations in CML 
patients with Imatinib resistance. Here, we suggest that 




The BaF3/WT and BaF3/T315I cells were kindly 
provided by Dr. Deininger (Huntsman Cancer Institute, 
Salt Lake City, UT), which inducibly expressed wild-
type Bcr-Abl and Bcr-Abl with the T315I mutation, 
respectively. BaF3/WT and BaF3/T315I cells were 
grown in Roswell Park Memorial Institute Media 1640 
(RPMI 1640), containing 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin. RPMI 1640; FBS and 
penicillin/streptomycin were purchased from GIBCO 
(Grand Island, NY). Imatinib was purchased from LC 
laboratories (Woburn, MA), and 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt (MTS) were purchased from 
Promega (Madison, WI). 
Enzyme binding assay
The enzyme binding assay of HS-543 was performed 
against a panel of 96 kinases using KINOMEscan assays 
at the Ambit Biosciences Corp (San Diego, CA). In brief, 
HS-543 was screened at 1 μM and results for primary 
screen binding interactions were reported as ‘% Ctrl’. % 
Ctrl Calculation = (HS-543 signal - positive control signal 
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/ negative control signal - positive control signal) x100, 
where negative control is DMSO (100% Ctrl), and positive 
control is control compound (0% Ctrl). Accordingly, lower 
percent of control (POC) values represent stronger hits [8].
Cell viability assay 
Cell viability of corresponding compounds was 
determined by MTS assay. The cells were seeded and 
treated onto 96-well plates at a density of 1 × 103 cells 
per well and incubated at 37 °C for 48 h. The cells were 
treated with either HS-543 or Imatinib at the indicated 
concentrations (0.001–10 μM). Then, 20 μL of MTS 
labeling mixture (1 mL of MTS/50 μL of phenazine 
methosulfate [PMS]) was added to each well. After 
incubation for 4 h, optical density (OD) was determined 
using a microplate reader by measuring the absorbance at 
wavelengths of 540 nm.
Western blotting
After the cells were treated with various 
concentrations of either HS-543 or Imatinib and incubated 
at 37°C for various times, they were collected and washed 
with cold phosphate-buffered saline (PBS). Then, the 
cells were lysed with a RIPA buffer (BIOSESANG, 
Korea) containing protease and phosphatase inhibitor 
cocktails (GenDEPOT, Barker, TX). The proteins were 
resolved by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS–PAGE), and transferred onto the 
nitrocellulose membranes. The blots were immunostained 
with the appropriate primary antibodies followed 
by secondary antibodies conjugated to horseradish 
peroxidase. Antibody binding was detected with an 
enhanced chemiluminescence reagent (Bio-Rad. Hercules, 
CA). Primary monoclonal antibodies against the following 
factors were used; p-Bcr-Abl (Tyr177), p-Crkl (Tyr207), 
p-Stat5 (Tyr694), Bcr-Abl, Crkl, Stat5, cleaved PARP, 
cleaved caspase-3, cytochrome c, survivin, Mcl-1, Bax 
and β-actin (Cell Signaling Technology, Danvers, MA). 
Secondary antibodies were purchased from Santa Cruz 
Biotechnology (Dallas, TX).
Immunofluorescence
BaF3/T315I cells were plated in 48-well plates 
with RPMI medium and treated with 1 μM HS-543 for 
various times. The cells were then suspended on poly-l-
lysine–coated slides, followed by Shandon Cytospin 3 
(Akribis Scientific, Cheshire, WA) for 3 min at 1000 rpm. 
Thereafter, the cells were fixed in 4% paraformaldehyde 
(PFA) for 15 min at room temperature and washed twice 
with PBS. The cells were blocked in 5% horse and goat 
serum in PBS for 1 h at room temperature, and then 
incubated in a humidified chamber at 4°C overnight with 
primary antibodies including rabbit anti-p-Bcr-Abl (Tyr177) 
and p-Stat5 (Tyr694) (Cell Signaling Technology). After 
washing twice with PBS, the cells were incubated with 
rabbit tetramethyl rhodamine isothiocyanate (TRITC) 
secondary antibody (Dianova, Germany) for 1 h at room 
temperature. They were also stained with 4,6-diamidino-
2-phenylindole (DAPI) to visualize the nuclei. The slides 
were then washed twice with PBS and covered with 
DAKO (Carpinteria, CA) before viewing with a confocal 
laser scanning microscope (Olympus, Japan). 
Also, after deparaffinization, immunostaining 
was performed, using 8-μm-thick sections of the tumor 
samples. The tissue sections were blocked with a normal 
goat or horse serum (Vector Laboratories. Burlingame, 
CA) for 1 h, and incubated at 4°C overnight in 1:50 
dilutions of p-Bcr-Abl (Tyr177) and p-Stat5 (Tyr694) (Cell 
Signaling Technology). After washing twice with PBS, 
the cells were incubated with rabbit TRITC secondary 
antibody for 1 h at room temperature. They were also 
stained with DAPI to visualize the nuclei. The slides were 
then washed twice with PBS and covered with DAKO 
before viewing with a confocal laser scanning microscope.
Cell cycle arrest
BaF3/T315I cells were plated in 10 cm dishes with 
RPMI medium and treated with HS-543 at the indicated 
concentrations (0.5–5 μM). The cells were collected 
and fixed in cold 70% ethanol at -25°C overnight. After 
washing with PBS, the cells were subsequently stained 
with 50 μg/mL propidium iodide (PI) and 100 μg/mL 
RNase A for 30 min at room temperature in the dark; then 
a flow cytometric analysis was performed to determine the 
percentage of cells in specific phases of sub G1 using a 
FACS Calibur flow cytometer (BD Biosciences. San Jose, 
CA). Flow cytometric data was analyzed using FlowJo 
software (Tree Star. Ashland, OR).
Hoechst staining and TUNEL staining
BaF3/T315I cells were plated in 48-well plates 
with RPMI medium and treated with HS-543 (1 μM). 
The cells were then suspended on poly-l-lysine-coated 
slides, followed by Shandon Cytospin 3 for 5 min at 1000 
rpm. They were then fixed in 4% PFA for 15 min at room 
temperature, washed with PBS, and stained with 1 μg/mL 
Hoechst 33342 (Cell Signaling Technology) for 20 min 
at room temperature. The stained cells were examined 
under a fluorescence microscope for evidence of nuclear 
fragmentation. Terminal deoxynucleotidyl transferase-
mediated nick end labeling (TUNEL) was subsequently 
performed using a TUNEL kit (Merck Millipore, 
Temecula, CA) in accordance to the manufacturer’s 
instructions.
Oncotarget1516www.impactjournals.com/oncotarget
Measurement of mitochondrial membrane 
potential
Mitochondrial membrane potential (MMP, ∆ψm) 
was assessed using Multi-Parameter Apoptosis Assay Kit 
(Cayman, Ann Arbor, MI). BaF3/T315I cells were treated 
with 1 μM HS-543 for 12 h. The cells were incubated with 
tetramethylrhodamine ethyl ester (TMRE), and DAPI 
staining at dark room condition. The cells were then 
suspended on poly-l-lysine-coated slides, followed by 
Shandon Cytospin 3 for 3 min at 1000 rpm. The slides 
were covered with DAKO before viewing with a confocal 
laser scanning microscope.
Analysis of cytochrome c localization
BaF3/T315I cells were treated with 1 μM HS-543 for 
10 h. To label the mitochondria, the cells were incubated 
with 100 nM mitochondrion-specific dye (MitoTracker® 
Red FM; Molecular Probes Inc., Eugene, OR) for 45 min 
at 37˚C prior to fixation. The cells were then suspended on 
poly-l-lysine-coated slides, followed by Shandon Cytospin 
3 for 3 min at 1000 rpm. They were then fixed in 4% PFA 
for 15 min at room temperature and washed with PBS. The 
cells were incubated at 4˚C overnight with cytochrome c 
antibody (Santa Cruz Biotechnology). After washing twice 
with PBS, the cells were incubated with mouse fluorescein 
isothiocyanate (FITC) secondary antibody (Dianova). The 
cells were also stained with DAPI to visualize the nuclei. 
The slides were then washed twice with PBS and covered 
with DAKO before viewing with a confocal laser scanning 
microscope.
Tumor xenograft study 
All animal experiments were performed in 
accordance with the guidelines of the INHA Institutional 
Animal Care and Use Committee (INHA IACUC at Inha 
University Medical School, under the authority of project 
number INHA 130318-197. The cells were harvested 
and mixed in PBS (200 μL/mouse). Six weeks old male 
BALB/c nude mice (Orient Bio, Korea) were inoculated 
with 1 × 105 cells in the flank. When the tumor size 
reached approximately 50-100 mm3, they were randomly 
divided into 4 groups of 5 mice. Then, these mice were 
given HS-543 or Imatinib by intraperitoneally 5 times 
a week for 14 days. The treat group was fed with either 
HS-543 (30 mg/kg and 50 mg/kg) or Imatinib (50 mg/kg), 
and the control group was fed vehicle. Tumor size and 
body weight were measured every 2 days. Tumor size was 
calculated using the formula 0.5 × length × width2
Immunohistochemisry
The tissue sections were blocked with normal goat 
or horse serum (Vector Laboratories) for 1 h, and incubated 
at 4°C overnight in 1:50 dilutions of cleaved caspase-3 
and proliferating cell nuclear antigen (PCNA) (Cell 
Signaling Technology). The sections were then incubated 
with biotinylated secondary antibodies (1:100) for 1 h. The 
sections were visualized by an avidin–biotin peroxidase 
complex solution using an ABC kit (Vector Laboratories), 
which were then washed in PBS and developed with a 
diaminobenzidine tetrahydrochloride substrate for 15 
min and then counterstained with hematoxylin. At least 
3 random fields of each section were examined at 400× 
magnification and analyzed using a computer image 
analysis system (Media Cybernetics. Rockville, MD).
Statistical analysis 
Data were expressed as the mean ± standard 
deviation (S.D.). Statistical analysis was performed using 
ANOVA and unpaired Student′s t-tests. The differences 
were considered statistically significant when p < 0.01.
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